Call us today: +44 (0) 20 3551 6634
International healthcare insurance policyholders may be interested to hear that researchers in the US have suggested that have found a key regulator of fat cell development that may provide a target for obesity and diabetes drugs.
According to scientists at The Scripps Research Institute and collaborating institutions, a protein called TLE3 that acts as a dual switch to turn on signals that stimulate fat cell formation and can also turn off those that keep fat cells from developing.
TLE3 works in partnership with a protein that is already the target of several diabetes drugs. It has been plagued by serious side effects.
"There is definitely a need for alternative drug targets," remarked Scripps Research Associate Professor Enrique Saez, one of the leaders of the study.
He added: "Our goal is to understand how fat cells form so that we can develop better treatments for obesity and related disorders."
Carrying too much fat can lead to insulin resistance and diabetes.
Expatriate Group.Delmon House,36-38 Church Road,Burgess Hill,West Sussex,RH15 9AE
Registered Address.35 Ballards Lane,London,N3 1XW
Tel: +44 (0)20 3551 6634Fax: +44 (0)870 428 5141Email: firstname.lastname@example.org
Short Term Healthcare Insurance
Travel Medical Insurance One Way Travel Insurance Single Trip Travel Insurance Annual Multi-Trip Travel Insurance Non UK Resident Travel Insurance Business Travel Insurance
About Us Useful Links Leave a Review Our Awards The Press Room Satisfaction Survey Downloads Legal Notice Underwriters Hospital List
Emergency Assistance information Short-Term Healthcare Working Abroad Insurance Thailand Health Insurance Family & Friend Benefits
Register as an Intermediary Opportunities for Brokers
Expatriate Group & Expatriate Healthcare are trading styles of Strategic Insurance Services Limited who is authorised and regulated by the Financial Conduct Authority (FCA). FCA Firm reference Number is 307133. Strategic Insurance Services Limited is authorised to carry on Regulated Activities in accordance with the permissions granted by the FCA under PART IV of the Financial Services and Markets ACT 2000.